Results 41 to 50 of about 2,525 (153)

Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis

Current Therapeutic Research
: Background: Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C β-lactamase inhibitor, including KPC from Klebsiella pneumoniae.
Reza Abniki, MS, Amirhossein Tashakor, MS, Melika Masoudi, PhD, Davood Mansury, PhD   +3 more
doaj   +1 more source

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales from patients with intra-abdominal infections: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2020

Journal of Microbiology, Immunology and Infection, 2023
Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj   +1 more source

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections

CPT: Pharmacometrics & Systems Pharmacology, 2019
Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunteers and ...
Pratik Bhagunde, Parul Patel, Mallika Lala, Kenny Watson, William Copalu, Ming Xu, Pooja Kulkarni, Katherine Young, Matthew L. Rizk   +8 more
doaj   +1 more source

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li, Fei Zeng, Jie Zhang, Yuangong Zhang, Wenjuan Yin   +4 more
wiley   +1 more source

Abstract Supplement

Pulmonary Medicine, Volume 2026, Issue 1, 2026.
 
Marzia Folegani, Semonti Nandi
wiley   +1 more source

Rectal Carriage of Sequence Type 307 Klebsiella pneumoniae High‐Risk Clone Harboring Multiple Carbapenemase Genes in Community Hospitals Gauteng, South Africa

MicrobiologyOpen, Volume 14, Issue 6, December 2025.
Graphical presentation of rectal carriage of carbapenem‐resistant Klebsiella pneumoniae, highlighting ST307 high‐risk clone and IncX3 plasmid‐associated blaOXA‐181. This study highlights the threat linked to horizontal gene transfer of AMR genes by epidemic plasmids from Klebsiella pneumoniae high‐risk clones to other bacterial species.
Kafilat Taiwo Salvador‐Oke, Johann Pitout, Gisele Peirano, Kathy‐Anne Strydom, Chanel Kingsburgh, Marthie Ehlers, Marleen Kock   +6 more
wiley   +1 more source

In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases

Journal of Global Antimicrobial Resistance
Objectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options.
Kengo Hayashi, Masahiro Suzuki, Yoshikazu Ishii, Yasufumi Matsumura, Kazuaki Matsumoto, Sho Saito, Yohei Doi   +6 more
doaj   +1 more source

Various Bacillus and Paenibacillus Spp. Isolated From Soil Produce Compounds With Potent Antimicrobial Activity Against Clinically Relevant Pathogens

MicrobiologyOpen, Volume 14, Issue 6, December 2025.
This study identified soil‐derived Bacillus and Paenibacillus strains with broad‐spectrum antimicrobial activity, including 97% inhibition of CREs by Paenibacillus profundus. Genome mining revealed biosynthetic gene clusters (NRPSs, PKSs, RiPPs) linked to antimicrobial production, highlighting their potential in combating antibiotic resistance. Created
Michael Moran, Hogan Turner, Joseph Yanchar, Joshua Preece, Gene Ahlborn, Richard Robison   +5 more
wiley   +1 more source

Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES‐1 by enmetazobactam and tazobactam

FEBS Letters, Volume 599, Issue 22, Page 3284-3300, November 2025.
Antimicrobial resistance (AMR) is of huge importance, resulting in over 1 million deaths each year. Here, we describe how a new drug, enmetazobactam, designed to help fight resistant bacterial diseases, inhibits a key enzyme (GES‐1) responsible for AMR. Our data show it is a more potent inhibitor than the related tazobactam, with high‐level computation
Michael Beer, Philip Hinchliffe, Marko Hanževački, Christopher R. Bethel, Catherine L. Tooke, Marc W. Van der Kamp, Krisztina M. Papp‐Wallace, Robert A. Bonomo, Stuart Shapiro, Adrian J. Mulholland, James Spencer   +10 more
wiley   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source